• Clinical data 90%
  • Efficacy 80%
  • Security 70%
  • Toxicity 30%

Urtica dioica
Radix Urticae


Urtica dioica L. Urtica gracilis Ait., U. major Kanitz., U. urens maxima Blackw.

General appearance

Rhizome cylindrical and tapering, occasionally branched, up to about 6mm thick at upper end; outer surface yellowish-brown; internodes with deep longitudinal furrows, numerous smooth, very thin and wiry roots arising from the nodes; in the outer part, inner surface creamy white with a central hollow; fracture fibrous and tough. Root greyish-brown, irregularly twisted, about 5mm thick, distinct longitudinal furrows; hollow in cross-section, cut surface white; fracture fibrous and tough.

Major chemical constituents

A large number of compounds of different polarity and belonging to various chemical classes, including fatty acids, terpenes, phenylpropanes, lignans, coumarins, triterpenes, ceramides, sterols and lectins, have been isolated from Radix Urticae. Among these are oxalic acid, linoleic acid, 14-octacosanol, 13-hydroxy-9-cis,11-trans-octadecadienoic acid, a-dimorphecolic acid (9-hydroxy- 10-trans,12-cis octadecadienoic acid), scopoletin, p-hydroxybenzaldehyde, homovanillyl alcohol, b-sitosterol, stigmasterol, 24-R-ethyl-5a-cholestan- 3b,6a-diol, campesterol, daucosterol (and related glycosides), secoisolariciresinol-9-O-b-D-glucoside, neoolivil, oleanolic acid, ursolic acid, Urtica dioica agglutinin and polysaccharides RP1–RP5.

Medicinal uses

Uses supported by clinical data

Symptomatic treatment of lower urinary tract disorders (nocturia, polyuria, urinary retention) resulting from BPH stages I and II, as defined by Alken, in cases where diagnosis of prostate cancer is negative.

Uses described in pharmacopoeias and traditional systems of medicine

As a diuretic and for the treatment of rheumatism and sciatica.

Uses described in folk medicine, not supported by experimental or clinical data

Treatment of asthma, coughs, dandruff, diabetes, diarrhoea, eczema, fever, gout, haemorrhoids, nose bleeds, scurvy, snakebites and tuberculosis. The plant has also been used to stop uterine bleeding after childbirth, increase lactation and promote hair growth, and as a vermifuge.

Pharmacology of Urtica dioica

Experimental pharmacology

Anti-inflammatory activity

An ethanol extract of Radix Urticae inhibited the activity of human leukocyte elastase and reduced the amount of the enzyme released by activated polymorphonuclear granulocytes during the inflammatory response. The extract also inhibited degradation of a peptide substrate in vitro by human leukocyte elastase (IC50 3.6mg/ml) and bovine elastin (IC50 68mg/ml). Intragastric administration of a polysaccharide fraction isolated from Radix Urticae to rats (40mg/kg body weight) suppressed carrageenan-induced footpad oedema for up to 20h. The activity of the polysaccharides was comparable to that of indometacin (10mg/kg body weight).

Lymphocyte proliferation

A lyophilized aqueous extract (10mg/ml) and a 40% alcohol extract of the roots (100mg/ml) stimulated human lymphocyte proliferation in vitro by 63% and 100%, respectively. Polysaccharides isolated from an aqueous root extract induced human lymphocyte proliferation in vitro (10–100mg/ml). An ethyl acetate extract of the roots induced cell differentiation in human promyelocytic leukaemia HL-60 cells in vitro (ED50 4mg/ml). Urtica dioica agglutinin (500ng/ml), however, inhibited lymphocyte proliferation and the binding of epidermal growth factor to its receptor on A431 epidermoid cancer cells in vitro. The lectin also exhibited immunomodulatory effects on T lymphocytes in a dose-dependent manner. Urtica dioica agglutinin bound to the cell membrane of prostatic hyperplastic cells and inhibited their proliferation.

Effect on benign prostatic hyperplasia
Effect on sex hormone-binding globulin

Sex hormone-binding globulin (SHBG) is a blood plasma protein that binds to circulating androgens and estrogens, thereby regulating their free concentration in plasma. The plasma membrane of the human prostate contains specific SHBG receptors, and SHBG appears to play a role in the development of BPH A 10% hydroalcoholic extract of the root reduced the binding capacity of SHBG (isolated from human plasma) for 5a-dihydrotestosterone by 67% in vitro. An aqueous extract of the root (0.6–10.0mg/ml) inhibited the binding of 125I-labelled SHBG to human prostate membranes in vitro. The lignan, secoisolariciresinol, and a mixture of the isomeric compounds 13-hydroxy 9- cis,11-trans-octadecadienoic acid and 9-hydroxy-10-trans,12-cis-octadecadienoic acid isolated from a methanol root extract, reduced the binding of SHBG to 5a-dihydrotestosteron. Secoisolariciresinol and its main intestinal transformation products, (-)-3,4 divanillyltetrahydrofuran and enterofuran, displaced the binding of 5a-dihydrotestosterone to SHBG in vitro by 60%, 95% and 73%, respectively.

Enzymatic activity

Intragastric administration of a 30% ethanol extract of the root to male mice inhibited the activities of 5a-reductase and aromatase (ED50 14.7 and 3.58mg/ml, respectively). However, a hydroalcoholic extract of the root dissolved in dimethyl sulfoxide did not inhibit the activity of 5a-reductase from human prostate cells in vitro (up to 500mg/ml). A standardized hydroalcoholic extract of the roots (IC50 338mg/ml) inhibited aromatase activity in vitro. A heptane-soluble fraction of the extract was the most effective inhibitor (IC50 9mg/ml). Both ursolic acid and 14-octacosanol isolated from a methanol extract of the roots inhibited the activity of aromatase in vitro. 9 Hydroxy-10-trans,12-cis-octadecadienoic acid isolated from the roots inhibited the activityof aromatase in vitro. Butanol, ether, ethylacetate and hexane extracts of the roots inhibited the activity of sodium- and potassium-adenosine triphosphatase isolated from prostatic hyperplastic cells by 27.6–81.5%. In addition, steroidal components of the roots, stigmast-4-en-3-one, stigmasterol and campesterol (1mmol/l to 1mmol/l), inhibited sodium- and potassium-adenosine triphosphatase activity by 23–67%.

Effect on prostate growth

Intragastric administration of a hexane extract of the roots (1.28 g daily) to castrated rats did not inhibit prostate growth stimulated by testosterone or dihydrotestosterone. Intraperitoneal administration of a hydroalcoholic extract of the roots (20mg/kg body weight) suppressed testosterone-stimulated increases in prostate weight and prostatic ornithine decarboxylase activity in castrated rats. Daily oral administration of a hydroalcoholic extract of the root to dogs with BPH (30mg/kg body weight) decreased prostate volume by 30% after 100 days of treatment. The effect of various root extracts was assessed after implantation of the fetal urogenital sinus into the prostate gland of adult mice. Intragastric administration of a butanol, cyclohexane or ethyl acetate extract of the root (0.25 ml/daily for 3 weeks) had no effect on the development of BPH in mice. However, intragastric administration of the same dose of a 20% methanol extract of the root reduced the development of BPH by 51.4%.


The LD50 of an aqueous extract or infusion of the roots after intravenous administration
to rats was 1721mg/kg body weight and 1929mg/kg body weight, respectively.
Oral administration of an infusion of the roots to rats was well tolerated at doses up to 1310mg/kg body weight.

Clinical pharmacology
Benign prostatic hyperplasia
Placebo-controlled clinical trials

Three double-blind, placebo-controlled clinical trials have assessed the efficacy of oral administration of Radix Urticae for the symptomatic treatment of lower urinary tract disorders resulting from BPH. One study assessed the efficacy of a 20% methanol extract of the roots in 50 men with BPH stages I and II. A significant increase in urine volume (by 43.7%; P = 0.027) and a significant decrease in serum levels of SHBG (P = 0.0005) was observed in patients treated with 600mg extract daily for 9 weeks. A modest increase in maximum urinary flow of 8% was also observed in the treated group; however, it was not significant. Another study assessed the efficacy of a 20% methanol extract in 40 men with BPH. Treatment with 1200mg extract daily for 6 weeks decreased the frequency of micturition and serum levels of SHBG. The third study assessed the efficacy of a methanol extract in the treatment of 32 men with BPH stage I. A 4–14% increase in average urinary flow and a 40–53% decrease in postvoid residual volume were observed in patients treated with 600 mg extract daily for 4–6 weeks.

Clinical trials without controls

Numerous clinical trials without controls have assessed the efficacy of oral administration of various Radix Urticae extracts (20% methanol or 30–45% ethanol) for the symptomatic treatment of lower urinary tract disorders (nocturia, polyuria, dysuria, urine retention) resulting from BPH. One trial assessed the efficacy of a 40% ethanol extract of the roots in 67 men with BPH. Treatment with 5ml daily for 6 months decreased nocturia and postvoid residual volume, but did not reduce prostate enlargement. In another trial, a 20% methanol extract of the roots was assessed in 89 men with BPH. Treatment with 600mg daily decreased the postvoid residual volume in 75% of patients after 3–24 months. In a study of 26 men with BPH stage I or II, a decrease in prostate volume was observed in 54% of patients, and a decrease in postvoid residual volume was observed in 75% of patients, after treatment with 1200mg methanol extract daily for 3–24 weeks. Ten men with BPH were treated with 30–150 drops of a 45% ethanol extract of the root daily for 30 days. After treatment, the postvoid residual volume decreased by 66%. In a study of 39 men with BPH stages I–III, an improvement in urinary flow, and a reduction in postvoid residual volume, nocturia and polyuria were seen in 95% of patients after 6 months of treatment with a 20% methanol extract (600–1200mg daily). Twenty-seven men with BPH stages I and II were treated with a 20% methanol extract of the roots for 3.5 months. Postvoid residual volume decreased significantly in 75% of patients (P < 0.001), and maximum urinary flow increased significantly in 50% of patients (P < 0.002).
Three large-scale multicentre studies involving 14033 men with BPH assessed the efficacy of a 20% methanol extract. In one study, a decrease in nocturia and polyuria was seen in 91% of patients after 6 months of treatment. In another study, a 50% decrease in nocturia was observed in patients treated with 1200mg extract daily for 10 weeks. In the third study, significant improvements in both urinary flow and postvoid residual volume were observed in 4480 patients treated with 600–1200mg extract daily for 20 weeks (P < 0.01).

Effects on prostate morphology

Three studies without controls examined the effect of various methanol extracts Urtica dioica on prostate morphology. Prostate cells were obtained from patients with BPH by needle biopsy, and were analysed for morphological changes before and after treatment. In two of the studies, cells were taken from the patients at various intervals during treatment. In the third study, cells were obtained once from the patients, and treatment with the extract was carried out in vitro. In the first study, 31 men with BPH stages I and II were treated orally with 1200mg of a 20% methanol root extract daily for 20 weeks. Prostate cells were analysed every 4 weeks by fluorescent microscopy. After 4–16 weeks of treatment, an increase in nuclear volume, as well as hydropic swelling and vacuolization of the cytoplasm, were observed. In the second study, prostate cells from four men with BPH stage I were examined by electron microscopy. After 6 months of oral treatment with a 20% methanol extract (1200mg daily), a reduction in the activity of smooth muscle cells and an increase in the secretory activity of glandular epithelial cells were observed. In the third study, prostate glandular epithelial cells from 33 patients with BPH were analysed by fluorescent microscopy following incubatio of the cells in vitro with a 20% methanol extract of the root. Treatment with the extract caused an increase in nuclear volume, loosening of chromatin and hydropic swelling of the cytoplasm. In addition, the number of homogeneous secretory granules was reduced, indicating a reduction in the biological activity of these cells.


Radix Urticae is contraindicated in cases of known allergy to plants of the Urticaceae family. Owing to its effects on androgen and estrogen metabolism, the use of Radix Urticae during pregnancy and lactation and in children under the age of 12 years is contraindicated.


Radix Urticae relieves the symptoms associated with BPH but does not have an effect on the size of the prostate. If symptoms worsen or do not improve, or in cases of blood in the urine or acute urinary retention, contact a physician.

News and Journals

1. British herbal pharmacopoeia. London, British Herbal Medicine Association, 1996.
2. Deutsches Arzneibuch. Stuttgart, Deutscher Apotheker Verlag, 1998.
3. Bombardelli E, Morazzoni P. Urtica dioica L. Fitoterapia, 1997, 68:387–402.
4. Blaschek W et al., eds. Hagers Handbuch der pharmazeutischen Praxis. Folgeband 2:
Drogen A–K, 5th ed. Berlin, Springer-Verlag, 1998.
5. Farnsworth NR, ed. NAPRALERT database. Chicago, University of Illinois at
Chicago, IL, February 9, 1998 production (an online database available directly
through the University of Illinois at Chicago or through the Scientific and Technical
Network [STN] of Chemical Abstracts Services).
6. Patten G. Urtica. Australian Journal of Medical Herbalism, 1993, 5:5–13.
7. Bisset NG. Herbal drugs and phytopharmaceuticals. Boca Raton, FL, CRC Press, 1994.
8. Grieve M. A modern herbal. Vol. II. New York, NY, Dover Publications, 1981.
9. Bedevian AK. Illustrated polyglottic dictionary of plant names in Latin, Arabic, Armenian,
English, French, German, Italian and Turkish languages. Cairo, Argus & Papazian Press,1936.
10. Bruneton J. Pharmacognosy, phytochemistry, medicinal plants. Paris, Lavoisier, 1995.
11. Tutin TG et al., eds. Flora Europae. Vol. 4. Cambridge, Cambridge University Press, 1976.
12. Quality control methods for medicinal plant materials. Geneva, World Health Organization, 1998.
13. European pharmacopoeia, 3rd ed. Strasbourg, Council of Europe, 1996.
14. Guidelines for predicting dietary intake of pesticide residues, 2nd rev. ed. Geneva, World
Health Organization, 1997 (document WHO/FSF/FOS/97.7).
15. Willer F, Wagner H, Schecklies E. Urtica root extract. Deutsche Apotheker Zeitung, 1991, 131:1211–1217.
16. Samtleben R, Boos G, Wagner H. Novel enzyme-linked immunoassay for the quantitation
of Urtica dioica agglutinin (UDA) in stinging nettle extracts and human excretions.
Phytomedicine, 1996, 2(Suppl. 1):134.
17. ESCOP monographs on the medicinal uses of plant drugs. Fascicule 2. Elburg, European
Scientific Cooperative on Phytotherapy, 1996.
18. Gansser D, Spiteller G. Plant constituents interfering with human sex hormonebinding
globulin. Evaluation of a test method and its application to Urtica dioica root
extracts. Zeitschrift für Naturforschung, 1995, 50c:98–104.
19. Kraus R, Spiteller G, Bartsch W. (10E,12Z)-9-Hydroxy-10,12-octadecadiensäure, ein
Aromatase-Hemmstoff aus dem Wurzelextrakt von Urtica dioica. Liebigs Annelen der
Chemie, 1990, 12:1205–1214.
20. Schilcher H, Effenberger S. Scopoletin und b-Sitosterol—zwei geeignete Leitsubstanzen
für Urticae radix. Deutsche Apotheker Zeitung, 1986, 126:79–81.
21. Wagner H et al. Lektine und Polysaccharide—die Wirkprinzipien der Urtica dioica
Wurzel. In: Boos G, ed. Benigne Prostatahyperplasie. Frankfurt, PMI, 1994.
22. Bauer HW et al. Endokrine Parameter während der Behandlung der benignen
Prostatahyperplasie mit ERU. In: Bauer HW, ed. Benigne Prostatahyperplasie II, klinische
und experimentelle Urologie 19. Munich, Zuckschwerdt, 1988.
23. Belaiche P, Lievoux O. Clinical studies on the palliative treatment of prostatic
adenoma with extract of Urtica root. Phytotherapy Research, 1991, 5:267–269.
24. Dathe G, Schmid H. Phytotherapie der benignen Prostatahyperplasie (BPH). Doppelblindstudie
mit Extraktum Radicis Urticae (ERU). Urologie [B], 1987, 27:223–226.
25. Djulepa J. Zweijährige Erfahrung in der Therapie des Prosta-Syndroms. Ärztliche
Praxis, 1982, 34:2199–2202.
26. Feiber H. Sonographische Verlaufsbeobachtungen zum Einfluss der medikamentösen
Therapie der benignen Prostatahyperplasie (BPH). In: Bauer HW, ed. Benigne
Prostatahyperplasie II, klinische und experimentelle Urologie 19. Munich, Zuckschwerdt, 1988.
27. Fisher M, Wilbert D. Wirkprüfung eines Phytopharmakons zur Behandlung der
benignen Prostatahyperplasie (BPH). In: Rutishauser G, ed. Benigne Prostatahyperplasie
III, klinische und experimentelle Urologie 22. Munich, Zuckschwerdt, 1992:79–83.
28. Friesen A. Statistische Analyse einer Multizenter-Langzeitstudie mit ERU. In: Bauer
HW, ed. Benigne Prostatahyperplasie II, klinische und experimentelle Urologie 19. Munich,
Zuckschwerdt, 1988:121–130.
29. Goetz P. Die Behandlung der benignen Prostatahyperplasie mit Brennesselwurzeln.
Zeitschrift für Phytotherapie, 1989, 10:175–178.
30. Sonnenschein R. Untersuchung der Wirksamkeit eines prostatotropen Phytotherapeutikums
(Urtica plus) bei benigner Prostatahyperplasie und Prostatitis—eine
prospektive multizentrische Studie. Urologie [B], 1987, 27:232–237.
31. Stahl HP. Die Therapie prostatischer Nykturie. Zeitschrift für Allgemeine Medizin, 1984, 60:128–132.
32. Tosch U et al. Medikamentöse Behandlung der benignen Prostatahyperplasie. Euromed, 1983, 6:1–3.
33. Vahlensieck W. Konservative Behandlung der benignen Prostatahyperplasie. Therapiewoche Schweiz, 1986, 2:619–624.
34. Vandierendounck EJ, Burkhardt P. Extractum radicis urticae bei Fibromyoadenom der Prostata mit nächtlicher Pollakisurie. Therapiewoche Schweiz, 1986, 2:892–895.
35. Vontobel HP et al. Ergebnisse einer Doppelblindstudie über die Wirksamkeit von
ERU-Kapseln in der konservativen Behandlung der benignen Prostatahyperplasie. Urologie [A], 1985, 24:49–51.
36. Koch E. Pharmacology and modes of action of extracts of Palmetto fruits (Sabal
Fructus), stinging nettle roots (Urticae Radix) and pumpkin seed (Cucurbitae Peponis
Semen) in the treatment of benign prostatic hyperplasia. In: Loew D, Rietbrock N,
eds. Phytopharmaka in Forschung und klinischer Anwendung. Darmstadt, Verlag Dietrich Steinkopf, 1995:57–79.
37. Wagner H et al. Search for the antiprostatic principle of stinging nettle (Urtica dioica) roots. Phytomedicine, 1994, 1:213–224.
38. Suh N et al. Discovery of natural product chemopreventive agents utilizing HL-60 cell differentiation as a model. Anticancer Research, 1995, 15:233–239.
39. Wagner H et al. Studies on the binding of Urtica dioica agglutinin (UDA) and other
lectins in an in vitro epidermal growth factor receptor test. Phytomedicine, 1995, 4:287–290.
40. Sinowatz F et al. Zur parakrinen Regulation des Prostatawachstums: Besteht eine
Wechselwirkung zwischen dem basalen Fibroblasten-Wachstumsfaktor und dem
Lektin UDA? In: Boos G, ed. Benigne Prostatathyperplasie. Frankfurt, PMI, 1994.
41. Schmidt K. The effect of an extract of Radix Urticae and various secondary extracts
on the SHBG of blood plasma in benign prostatic hyperplasia. Fortschritte der Medizin, 1983, 101:713–716.
42. Hryb DJ et al. The effects of extracts of the roots of the stinging nettle (Urtica dioica)
on the interaction of SHBG with its receptor on human prostatic membranes. Planta Medica, 1995, 61:31–32.
43. Schöttner M, Gansser D, Spiteller G. Lignans from the roots of Urtica dioica and their
metabolites bind to human sex hormone-binding globulin (SHBG). Planta Medica, 1997, 63:529–532.
44. Hartmann RW, Mark M, Soldati F. Inhibition of 5a-reductase and aromatase by PHL- 00801 (Prostatonin®), a combination of PY 102 (Pygeum africanum) and UR 102 (Urtica
dioica) extracts. Phytomedicine, 1996, 3:121–128.
45. Rhodes L et al. Comparison of finasteride (Proscar®), a 5a-reductase inhibitor, and
various commercial plant extracts in in vitro and in vivo 5a-reductase inhibition.
Prostate, 1993, 22:43–51.
46. Gansser D, Spiteller G. Aromatase inhibitors from Urtica dioica roots. Planta Medica, 1995, 61:138–140.
47. Hirano T, Homma M, Oka K. Effects of stinging nettle root extracts and their
steroidal components on the Na+, K+-ATPase of the benign prostatic hyperplasia. Planta Medica, 1994, 60:30–33.
48. Scapagnini U, Friesen A. Urtica dioica-Extrakt und Folgesubstanzen im Tierversuch.
Klinische und Experimentelle Urologie, 1992, 22:138–144.
49. Daube G. Pilotstudie zur Behandlung der benignen Prostatahyperplasie bei Hunden
mit Extractum Radicis Urticae (ERU). In: Bauer HW, ed. Benigne Prostatahyperplasie
II, klinische und experimentelle Urologie 19. Munich, Zuckschwerdt, 1988:63–66.
50. Lichius JJ, Muth C. The inhibiting effects of Urtica dioica root extracts on experimentally
induced prostatic hyperplasia in the mouse. Planta Medica, 1997, 63: 307–310.
51. Maar K. Rückbildung der Symptomatik von Prostataadenomen. Fortschritte der Medizin, 1987, 105:50–52.
52. Romics I. Observations with Bazotona® in the management of prostatic hyperplasia.
International Urology and Nephrology, 1987, 19:293–297.
53. Ziegler H. Cytomorphological study of benign prostatic hyperplasia under treatment
with extract. Radicis Urticae (ERU)—preliminary results. Fortschritte der Medizin, 1982, 39:1823–1824.
54. Oberholzer M et al. Elektronenmikroskopische Ergebnisse bei medikamentös
behandelter benigner Prostatahyperplasie. In: Bauer HW, ed. Benigne Prostatahyperplasie. Munich, Zuckschwerdt, 1986.
55. Ziegler H. Investigations of prostate cells under the effect of extract Radix Urticae
(ERU) by fluorescent microscopy. Fortschritte der Medizin, 1983, 101:2112–2114.
56. Blumenthal M et al., eds. The complete German Commission E monographs. Austin, TX, American Botanical Council, 1998.